History

While manufacturing of commercial therapeutic peptides started in 1952 in Malmo, Sweden the PolyPeptide Group was officially founded in 1996 through the acquisition of the Peptech facility in Malmo, Sweden, followed by the establishment of a US subsidiary in Torrance (USA) in 1997.

The Group has since then expanded through a series of acquisitions, the last of which being the NeoMPS Group in 2007, and through internal growth, the latest addition being our site in Ambernath India which is dedicated to the manufacturing of generic peptides and was inaugurated in 2009.

Today, the Group has 6 different manufacturing sites across the globe, two in the US, three in Europe and one in India serving clients with peptide needs throughout the world.

1952

START OF COMMERCIAL THERAPEUTIC PEPTIDE MANUFACTURE AT MALMÖ IN SWEDEN

1996

FOUNDING OF THE POLYPEPTIDE GROUP IN HILLERØD, DENMARK AND TORRANCE, USA

1997

OPERATIONS START IN TORRANCE, USA

1998

ACQUISITION OF WHERL GMBH AND PRAGUE POLYPEPTIDE LABORATORIES SRO.

2006

START OF CONSTRUCTION OF INDIAN FACILITY NEAR MUMBAI

2007

ACQUISITION OF THE NEOMPS GROUP

2008

OPENING OF NEW MANUFACTURING PLANT IN STRASBOURG, FRANCE

2009

ACQUISITION OF A NEW BUILDING IN TORRANCE, USA EXPANSION IN MALMÖ, SWEDEN INAUGURATION OF THE FACILITY IN INDIA

2012

22 COMMERCIAL PRODUCTS MANUFACTURED AT POLYPEPTIDE

2017

POLYPEPTIDE GROUP ACQUIRED THE NEW BUSINESS AND OPERATIONS OF LONZA IN BRAINE-L’ALLEUD, BELGIUM

2019

MORE THAN 30 APPROVED ACTIVE PHARMACEUTICAL INGREDIENTS